ASCO GU 2020 Kidney Cancer - Results from #20

Viewing 21-40 of 57 articles

ASCO GU 2020: Delayed Versus Upfront Cyto-Reductive Nephrectomy for Metastatic Kidney Cancer

ASCO GU 2020: Report from the Consensus Panel Meeting - Genetic Risk Assessment for Hereditary Renal Cell Carcinoma

ASCO GU 2020: Emerging Therapies in Renal Cell Carcinoma: From PARP Inhibition to Novel Immunotherapeutics

ASCO GU 2020: Combined Dual Checkpoint Inhibition and Stereotactic Body Radiotherapy in the Metastatic Renal Cell Carcinoma Setting (RADVAX RCC).

ASCO GU 2020: Clinically Useful Biomarkers: Ready for Prime Time in 2020?

ASCO GU 2020: Non-Clear Cell Renal Cell Carcinoma — Molecular Pathways and Management Options

ASCO GU 2020: Best of Journals: Renal Cell Carcinoma — The Medical Oncologist Perspective

ASCO GU 2020: Overall Survival and Independent Review of Response in CheckMate 214 with 42-month Follow-Up: First-Line Nivolumab + Ipilimumab versus Sunitinib in Patients with Advanced Renal Cell Carcinoma

ASCO GU 2020: Renal Cell Carcinoma: The Virtual Biopsy

ASCO GU 2020: Emerging Therapies in RCC: From PARP Inhibitors to Novel Immunotherapeutics

ASCO GU 2020: Molecular Pathways and Management Options in Non-Clear Cell Renal Cell Carcinoma

ASCO GU 2020: Delayed Versus Up-Front Cytoreductive Nephrectomy for Metastatic Disease

ASCO GU 2020: Current Triggers for Intervention in Patients on Active Surveillance

ASCO GU 2020: Final Analysis of the CheckMate 025 Trial Comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma

ASCO GU 2020: NIVOREN GETUG-AFU 26 Translational Study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab

ASCO GU 2020: Clinically Useful Biomarkers: Ready for Prime Time in 2020? - A Urologists Report

ASCO GU 2020: Best of the Journals – Renal Cell Carcinoma: Pathology Perspective

ASCO GU 2020: A Novel Clinical Decision Aid to Support Personalized Treatment Selection for Patients with cT1 Renal Cortical Masses: Results from A Multi-Institutional Competing Risks Analysis Including Performance Status and Comorbidity

ASCO GU 2020: Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: A Propensity Score-Based Analysis

ASCO GU 2020: Best of the Journals – Renal Cell Carcinoma: Surgery Perspective

1
2
3